KalVista Pharmaceuticals (KALV) Projected to Post Earnings on Thursday

KalVista Pharmaceuticals (NASDAQ:KALV) is expected to be releasing its Q2 2026 results before the market opens on Thursday, December 11th. Analysts expect the company to announce earnings of ($1.06) per share and revenue of $6.0330 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, December 19, 2025 at 12:00 AM ET.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. On average, analysts expect KalVista Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $16.16 on Wednesday. The stock’s fifty day simple moving average is $12.47 and its 200-day simple moving average is $13.09. The company has a market capitalization of $816.89 million, a price-to-earnings ratio of -4.09 and a beta of -0.14. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $17.28.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the sale, the chief financial officer directly owned 10,529 shares in the company, valued at $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 31,329 shares of company stock worth $437,371. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $55,000. Tower Research Capital LLC TRC lifted its position in shares of KalVista Pharmaceuticals by 816.8% in the second quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after buying an additional 7,180 shares during the last quarter. Sei Investments Co. bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $145,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of KalVista Pharmaceuticals during the 2nd quarter worth approximately $151,000.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on KALV shares. Citizens Jmp reduced their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $26.63.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).